
    
      A Phase 1, Multicenter, Dose Escalation Study of CAT-8015 in Children, Adolescents and Young
      Adults with Refractory CD22+ Acute Lymphoblastic Leukemia (ALL) or Non-Hodgkin Lymphoma (NHL)
      to estimate the maximum tolerated cummulative dose (MTCD), defined as the highest dose and
      number of doses that can be safely administered to a participant, and to establish a safe
      dose, based on the MTCD, for subsequent clinical testing.
    
  